All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or Myeloma crowd.

The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

How might the iberdomide safety profile be critical for its future applications?

During the 18th International Myeloma Workshop, the Multiple Myeloma Hub spoke with Sagar Lonial, Winship Cancer Institute of Emory University, Atlanta, US. We asked, How might the iberdomide safety profile be critical for its future applications?

How might the iberdomide safety profile be critical for its future applications?

Lonial discusses the safety profile of iberdomide (CC-220) in combination with other agents. He also mentions the promising safety profile as well as adverse events, such as myelosuppression.

 

Share: